Trial Profile
Study of sunitinib versus temsirolimus in patients with poor risk metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 09 Aug 2016 New trial record